Study in Patients With COPD
Phase 2
Completed
- Conditions
- COPD
- Registration Number
- NCT00215384
- Lead Sponsor
- Dey
- Brief Summary
The purpose of this study is to determine which dose of the investigational drug is the most safe and effective compared to the control drug.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
-History of COPD and cigarette smoking
Exclusion Criteria
- Clinical diagnosis of asthma.
- Chest X-ray that is diagnostic of a significant pulmonary disease other than COPD
- Disease of other major organ systems
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method The primary outcome variable is the measure of lung function.
- Secondary Outcome Measures
Name Time Method Change in lung function will be examined as a secondary outcome, as well as vital signs, physical examination, adverse even reporting, etc.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the investigational drug's efficacy in NCT00215384 COPD trial?
How does the investigational drug in NCT00215384 compare to standard-of-care bronchodilators for COPD management?
Are there specific biomarkers like FEV1 or inflammatory markers predicting response in NCT00215384 COPD patients?
What adverse events were reported in Dey's Phase 2 COPD trial NCT00215384 and how were they managed?
What other inhaled corticosteroids or phosphodiesterase inhibitors are being studied for COPD alongside Dey's compound?
Trial Locations
- Locations (1)
Research Site
🇺🇸Tacoma, Washington, United States
Research Site🇺🇸Tacoma, Washington, United States